New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control
This study reviewed the published data regarding the evidence of reduced CHG susceptibility, the cross-resistance with antibiotics, and the implications for infection control for S. aureus, coagulase-negative staphylococci, E. coli, K. pneumoniae, and P. aeruginosa. Despite incongruity in definitions of " resistance, " 12 increased CHG minimal inhibitory values of these pathogens have been described, and different mutations encoding for CHG efflux pumps have been identified. Clinical relevance of species with reduced susceptibility to CHG is debatable and cross-resistance with antibiotics remains controversial. However, so...
Source: Current Awareness Service for Health (CASH) - May 17, 2022 Category: Consumer Health News Source Type: news

New jab to help prevent urinary tract infections
In the coming months, the jab will be offered in a number of NHS hospitals as part of a landmark trial that will assess whether a single injection can stop cases caused by the common bacteria E. Coli. (Source: the Mail online | Health)
Source: the Mail online | Health - May 7, 2022 Category: Consumer Health News Source Type: news

Researcher, 26, left feeling so sick he 'wanted to die' after drinking shot of shigella
Jack Eberts, from Washington D.C., drunk a shot of the dysentery-causing bacteria for a vaccine trial. He became so ill that he faced stomach cramps, diarrhea, and even soiled himself. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2022 Category: Consumer Health News Source Type: news

Over 120,000 pounds of ground beef is recalled over E.coli contamination fears
The U.S. Food Safety and Inspection Service urged Americans who had contaminated burgers and ground beef to throw them out or take them back to the store. Products came from a facility in New Jersey. (Source: the Mail online | Health)
Source: the Mail online | Health - April 27, 2022 Category: Consumer Health News Source Type: news

Over 120,000 pounds of ground beef recalled over possible E.coli contamination
Over 120,000 pounds of ground beef products are being recalled by the company due to a possible E.Coli contamination. #groundbeefproducts (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2022 Category: Consumer Health News Source Type: news

Ground Beef Recall, Over 120,000 Pounds, Due To E. Coli Concerns
Routine U.S. Department of Agriculture ’s (USDA’s) Food Safety and Inspection Service (FSIS) testing found E. coli O103 in a Lakeside Refrigerated Services facility. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 27, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Food & Drink /food-drink Editors' Pick editors-pick pharma Source Type: news

Microplastics in Seawater May Harbor Parasites
Laboratory experiments find that Toxoplasma, Cryptosporidium, and Giardia can congregate on microplastic beads and fibers, suggesting they might make their way into and around the world ’s oceans by... (Source: The Scientist)
Source: The Scientist - April 26, 2022 Category: Science Tags: News & Opinion Source Type: news

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
Cape Town, South Africa, April 25, 2022 – Johnson & Johnson (the Company) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Sa...
Source: Johnson and Johnson - April 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stomach Flu (Gastroenteritis)
Title: Stomach Flu (Gastroenteritis)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 4/14/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - April 14, 2022 Category: Nutrition Source Type: news

Mayo Clinic Minute: What to do when sick with norovirus or 'stomach flu'
If you went out for the evening and woke up with a sudden bad stomach, chances are you might be experiencing viral gastroenteritis. That's the broad term for an infection in the intestines. Some call it "stomach flu." Gastroenteritis can be brought on by norovirus — a highly contagious viral infection most often spread through person-to-person contact or contaminated food or water, or by  ​touching contaminated surfaces. It can be quite severe for some people, but for… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 14, 2022 Category: Databases & Libraries Source Type: news

Notes from the Field: Enteropathogenic Escherichia coli Outbreak at a Child Care Center - Oregon, August 2021
This report describes an E. coli outbreak at an Oregon child care center. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 7, 2022 Category: American Health Tags: Children's Health Diseases & Conditions E. coli Infection MMWR Morbidity Mortality Weekly Report Outbreaks Child Care Source Type: news

Prevalence and Outcomes of Multi-Drug Resistant Blood Stream Infections Among Nursing Home Residents Admitted to an Acute Care Hospital
Conclusion: Nursing home residents have a high prevalence of MDRO-BSI, which is associated with higher risk of receiving inappropriate initial anti-infective therapy, higher cost, higher ICU LOS, and higher mortality. Our research adds new information about the prev alence of fungemia in this population. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 7, 2022 Category: Consumer Health News Source Type: news

New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news

Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news